New Options in Psychedelic Medicine Part 2: MDMA

While it does have risks that must be managed, MDMA has the potential to be an effective and powerful medicine for many people. Liminal’s team is trained to work with MDMA

New Options in Psychedelic Medicine Part 2: MDMA

In our last blog we discussed the new possibilities for legal access to psychedelic medicines since the recent executive order, “Accelerating Medical Treatments for Serious Mental Illness,” signed on April 18, 2026. While this order is working its way through the government, let’s talk about what medicines may be available in the next two years, and how they differ from ketamine therapy.

In the last newsletter, we discussed psilocybin, which experts believe may be the first psychedelic medicine to become FDA approved. Today, let’s talk about MDMA, which many people believe may be the second medication to be approved.

The chemist Alexander Shulgin was the first person to realize the healing potential of MDMA in 1976. He introduced psychotherapists to the medication and they began to use it for MDMA-assisted psychotherapy. Unfortunately, the legal use of MDMA ended in 1985, when the DEA classified it as an illegal drug, despite the testimony of many therapists and psychologists that this was an important therapeutic medication.

Current research in MDMA shows that it can be very useful for people with severe PTSD, and in some cases, it has cured PTSD. MDMA is not exactly like other psychedelics. It is often called an empathogen, because it produces intense feelings of empathy, and a sense of well being. It can evoke a deep feeling of self-empathy which may be how MDMA decreases symptoms of PTSD.

MDMA works by causing the brain to release ALL of its stored serotonin, and large amounts of dopamine, and norepinephrine, all of which are signaling chemicals in the brain. One effect of this, as with many psychedelics, is to cause new pathways to develop in the brain (“neurogenesis”). Johns Hopkins University has released a study that shows that MDMA may temporarily reopen a window for social learning. This may allow people to have a greater ability to bond with people around them.

Because MDMA, like other classical psychedelics, works in the serotonin and dopamine pathways, it cannot be taken with most antidepressant or psychiatric medications. These medications can block the activity of MDMA, and may also be able to cause serotonin syndrome, which can have deadly outcomes. For people who take these antidepressants, stopping them too quickly can also cause harmful destabilization that can undermine the healing effects of MDMA. (This is different from ketamine, which can safely be taken with most antidepressants or psychiatric medications.)

Another issue with MDMA is that it can cause an increase in heart rate and blood pressure. This could put people with high blood pressure, heart disease, or heart rate rhythm issues at risk of heart attacks or strokes. If MDMA is legalized, it will be important to use it with medical supervision due to these risks.

Currently, MDMA is not legal anywhere in the United States unless it is being used in specific research programs. MDMA is legal for use by psychiatrists in Australia, for treatment of PTSD.

The timeline for MDMA in the US is unclear. It failed its attempt to pass the FDA in 2024 and will require further research to show that it is safe and effective. This could take another 2 to 3 years, if not more, although practitioners in our field are hopeful that the Executive Order will speed this process up. Some have predicted that it may be approved as soon as early next year!

While it does have risks that must be managed, MDMA has the potential to be an effective and powerful medicine for many people. Liminal’s team is trained to work with MDMA, and will be ready to offer MDMA-assisted therapy as soon as it is available. Follow our newsletter and social media for updates as they happen!

Share Now :